Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
Wet AMD is a disease of the central portion of the retina (the macula) which is responsible for high visual acuity that allows for color vision, reading and facial recognition
Geographic Atrophy is a slowly progressing, yet damaging form of AMD. Approximately 5 million people have Geographic Atrophy worldwide, with disease prevalence increasing with age. It is characterized by regions of cell death in the retina.
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age. It is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.